Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study

BACKGROUND: Cluster of differentiation (CD) 73-targeted immunotherapy and CD73 inhibition may reduce adenosine production, which can augment the host and/or immunotherapy response to tumours. We aimed to assess the safety and tolerability, pharmacokinetics, and antitumour activity of oleclumab, an a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Shunsuke, Iwasa, Satoru, Koyama, Takafumi, Fujita, Tomoko, Sugibayashi, Ko, Murayama, Kosho, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700577/
https://www.ncbi.nlm.nih.gov/pubmed/36342599
http://dx.doi.org/10.1007/s10147-022-02242-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700577/
https://www.ncbi.nlm.nih.gov/pubmed/36342599
http://dx.doi.org/10.1007/s10147-022-02242-5

Ejemplares similares